Search results
Results From The WOW.Com Content Network
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [32] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. [44] [45] It is authorized for use ...
A COVID-19 vaccine black market enabled some individuals to buy illegal early access to a vaccine. [109] By mid-February 2021, China had arrested 80 people involved in vaccine contraband, and the Colombian government intercepted a freezer with 70 doses of a Chinese-manufactured vaccine that a traveler brought with her into the airport without ...
The global COVID-19 pandemic arrived in Europe with its first confirmed case in Bordeaux, France, on 24 January 2020, and subsequently spread widely across the continent. By 17 March 2020, every country in Europe had confirmed a case, [62] and all have reported at least one death, with the exception of Vatican City .
Top causes of death, according to the World Health Organization report for the calendar year 2001: [6] Causes of death in developing countries. Number of deaths. Causes of death in developed countries. Number of deaths. HIV-AIDS. 2,678,000. Ischaemic heart disease. 3,512,000.
COVID-19 vaccination in Africa. COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. [1] As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
A year into the pandemic, a half-million Americans (1 out of every 670 Americans) had died of COVID-19. Many people were affected by grief and loss. By the time a half-million Americans had died, one-third of Americans participating in a survey said they personally knew someone who had died this way.
COVID-19 portal. v. t. e. ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. [1] [2] For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. The vaccine was authorised in Japan in November 2023.
In this group, 8,298 tested positive, 45 were admitted to the ICU, and 35 died of COVID-19. This indicated 64.52% and 61.47% effectiveness in reducing COVID-19 cases for people aged 18–49 and 50 and older respectively. The vaccine was 94.95% and 92.18% effective in reducing ICU admissions, and 95.35% and 95.2% effective to prevent deaths.